This bispecific antibody comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds ErbB-3 can inhibit the proliferation of pancreatic cancer cells. It is capable of induceing ADCC (Dependent cell-mediated cytotoxicity) activity towards the EGFR amplified cell line, which is an important anti-tumour mechanism of action for therapeutic antibodies in cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.